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Objectives This study sought to assess the incidence of reocclusion and identification of predictors of angiographic failure
after successful chronic total occlusion (CTO) drug-eluting stent–supported percutaneous coronary intervention
(PCI).
Background Large registries have shown a survival benefit in patients with successful CTO PCI. Intuitively, sustained vessel
patency may be considered as a main variable related to long-term survival. Very few data exist about the angio-
graphic outcome after successful CTO PCI.
Methods The Florence CTO PCI registry started in 2003 and included consecutive patients treated with drug-eluting stents
for at least 1 CTO (3 months). The protocol treatment included routine 6- to 9-month angiographic follow-up.
Clinical, angiographic, and procedural variables were included in the model of multivariable binary logistic re-
gression analysis for the identification of the predictors of reocclusion.
Results From 2003 to 2010, 1,035 patients underwent PCI for at least 1 CTO. Of these, 802 (77%) had a successful
PCI. The angiographic follow-up rate was 82%. Reocclusion rate was 7.5%, whereas binary restenosis (50%) or
reocclusion rate was 20%. Everolimus-eluting stents were associated with a significantly lower reocclusion rate
than were other drug-eluting stents (3.0% vs. 10.1%; p  0.001). A successful subintimal tracking and re-entry
technique was associated with a 57% of reocclusion rate. By multivariable analysis, the subintimal tracking and
re-entry technique (odds ratio [OR]: 29.5; p  0.001) and everolimus-eluting stents (OR: 0.22; p  0.001) were
independently related to the risk of reocclusion.
Conclusions Successful CTO-PCI supported by everolimus-eluting stents is associated with a very high patency rate. Success-
ful subintimal tracking and re-entry technique is associated with a very low patency rate regardless of the type
of stent used. (J Am Coll Cardiol 2013;61:545–50) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.036Large registries have shown a survival benefit in patients
with successful chronic total occlusion (CTO) percutaneous
coronary intervention (PCI) as compared to unsuccessful or
unattempted CTO PCI (1–4). Intuitively, sustained vessel
patency may be considered as a main variable related to
long-term survival. Very few data exist about the angio-
graphic outcome of successful CTO PCI, because random-
ized studies comparing different types of stents had small
sample sizes; most registries did not include angiographic
follow-up; and sparse data are available from a few small
registries with a very low angiographic follow-up rate
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failure after successful drug-eluting stent (DES)–supported
CTO PCI.
See page 551
Methods
Patients and treatment. The Florence CTO PCI registry,
started in 2003, includes consecutive patients treated with
DES for at least 1 CTO. Details on this registry have been
previously published (4,10). CTO was defined as a coronary
obstruction with TIMI (Thrombolysis in Myocardial In-
farction) flow grade 0 with an estimated duration 3
months. The duration of the occlusion was determined by
the interval from the last episode of acute coronary syn-
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history of acute coronary syn-
dromes, from the first episode of
effort angina consistent with the
location of the occlusion or by a
previous coronary angiography.
In patients without a history of
angina and who were admitted
for an acute coronary syndrome
or ST-segment elevation acute
myocardial infarction with a def-
inite identification of the culprit
vessel, associated total occlusion
of a nonculprit vessel was consid-
ered as a chronic occlusion if
there was angiographic evidence
of filling the vessel through col-
laterals. The indication for the
percutaneous treatment of CTO was the demonstration of
viable myocardium in the territory of the occluded vessel by
echographic or scintigraphic provocative tests, whereas no
CTO angiographic characteristic was considered as an
absolute contraindication to PCI attempt. Thus, patients
with long occlusions, extensive calcification, bridging col-
laterals, a nontapered stump, or a side branch at the
occlusion site were included. Occlusion length was assessed
from the beginning of the occlusion to the distal antegrade
or retrograde vessel by filling from bridge collaterals or
collaterals provided by a coronary artery other than the
CTO vessel and using simultaneous contrast medium in-
jection in both right and left coronary arteries. All occlu-
sions were attempted using the anterograde or retrograde
approach and dedicated coronary wires (hydrophilic and
nonhydrophilic) and devices. The anterograde approach was
the first option treatment in all but right coronary ostium
CTO. Subintimal tracking and re-entry (STAR) technique
was used only after failed anterograde and retrograde ap-
proaches. Three types of DES were used during the study
period: first-generation sirolimus-eluting stent (Cypher,
Cordis Corp., Miami Lakes, Florida), first-generation
paclitaxel-eluting stent (Taxus Express or Taxus Liberté,
Boston Scientific, Natick, Massachusetts), and everolimus-
eluting stent (EES) (either Xience V, Abbott Vascular,
Santa Clara, California; or Promus, Boston Scientific).
Standard stent implantation techniques, including mini-
mum overlap between stents and routine post-dilation using
final high balloon pressure (16 atm) were used. All
patients were pre-treated with aspirin (300 mg/day) and
clopidogrel (loading dose 600 mg). Aspirin (300 mg/day)
was continued indefinitely and clopidogrel (75 mg/day) for
at least 12 months.
Procedural success was defined as a final diameter stenosis
30% with a TIMI flow grade 3 of the CTO vessel without
death, or Q-wave myocardial infarction, or emergency
coronary surgery. A Q-wave myocardial infarction was
Abbreviations
and Acronyms
CI  confidence interval(s)
CTO  chronic total
occlusion
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio(s)
OR  odds ratio(s)
PCI  percutaneous
coronary intervention
STAR  subintimal
tracking and re-entry
TIMI  Thrombolysis In
Myocardial Infarctiondefined as new Q waves in 2 or more contiguous leads inaddition to creatine kinase-myocardial band elevation. Cre-
atine kinase-myocardial band fraction was routinely assessed
12 h after PCI in all patients or at least 3 times every 6 h in
patients with recurrent chest pain.
All patients had scheduled clinical and electrocardio-
graphic examinations at 6 months and at 1 and 2 years. All
other possible information derived from hospital readmis-
sion or by the referring physician, relatives, or municipality
live registries were entered into the prospective database.
All patients with successful CTO PCI and without
moderate or severe renal insufficiency were scheduled for
angiographic follow-up at 6 to 9 months. Unscheduled
angiography was allowed based on clinical indication. An-
giographic parameters were assessed using a computer
analysis system (Innova 2100IQ, General Electric Health-
care Technologies, Little Chalfont, Buckinghamshire,
United Kingdom).
Endpoints. The primary endpoint of the study was reoc-
clusion of the CTO vessel at the scheduled or unscheduled
angiographic follow-up. The secondary endpoints were:
1) binary angiographic restenosis; 2) 1-year major adverse
cardiac events including death, myocardial infarction, and
target CTO vessel revascularization; and 3) definite CTO
stent thrombosis. Reocclusion was defined as a TIMI flow
grade 0 to 1 in the target vessel, whereas restenosis was
defined as 50% luminal narrowing at the segment site
including the stent and 5 mm proximal and distal to the
stent edges. For patients with multiple treated CTO, only
the first CTO attempted was considered for the analysis. All
deaths were considered cardiac unless otherwise docu-
mented. Stent thrombosis was defined according to the
Academic Research Consortium criteria (13).
Statistical analysis. Discrete data are summarized as fre-
quencies and continuous data as mean SD or median and
interquartile range. Chi-square test or Fisher exact test
analyses were used for comparison of categorical variables.
The multivariable analysis to evaluate the independent
contribution of clinical, angiographic, and procedural vari-
ables to reocclusion and in-segment restenosis was per-
formed by forward stepwise logistic regression analysis. The
following variables were tested: diabetes mellitus; renal
insufficiency; CTO stent length 40 mm; STAR tech-
nique; EES; year of the index procedure. Cumulative
survival analyses were performed using the Kaplan-Meier
method, and the difference between curves was assessed by
log-rank test. A multivariable analysis by forward stepwise
Cox proportional hazards model was performed to evaluate
the independent predictors of death, myocardial infarction,
and target CTO vessel revascularization. The following
variables were tested: age 75 years; diabetes mellitus;
previous myocardial infarction; renal insufficiency; acute
coronary syndrome at admission; left ventricular ejection
fraction 0.40; 3-vessel disease; CTO vessel; CTO stent
length 40 mm; STAR technique; EES; completeness of
revascularization; year of the index procedure. Interaction
between EES and year of the index procedure was tested
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hazards ratios (HRs), and their 95% confidence intervals
(CIs) were calculated.
A propensity score-matched analysis (1:1) was also per-
formed to reduce bias due to a different time frame in the
use of first-generation (paclitaxel- and sirolimus-eluting)
and second-generation (everolimus-eluting) DES. An op-
timal data-matching technique was performed using pro-
pensity score as caliper. Propensity score analysis was
performed with the use of a logistic regression model from
which the probability for the use of EES was calculated for
each patient. The variables entered into the model were: age
75 years; male; diabetes mellitus; left ventricular ejection
fraction 0.40; 3-vessel disease; CTO vessel; CTO length
20 mm; CTO vessel reference diameter 2.5 mm; CTO
heavy calcification; CTO stent length 40 mm; adjunctive
rotational atherectomy; STAR technique; completeness of
revascularization. Model discrimination was assessed with
the C-statistic and goodness of fit with the Hosmer-
Lemeshow test.
All tests were 2-tailed. A p value 0.05 was considered
significant. Analyses were performed using the software
package SPSS (version 11.5, SPSS Inc., Chicago, Illinois).
Results
From 2003 to 2011, 1,035 patients underwent a PCI
attempt for at least 1 CTO. Of these, 802 (77%) had a
successful PCI.
Table 1 summarizes the baseline patient characteristics.
The mean age was 68  11 years; 25% of patients had
diabetes mellitus; and one-half of patients had a history of
myocardial infarction. The majority of patients had multi-
vessel disease, and 3-vessel disease was revealed in 49%.
One-hundred and twenty-two patients were treated for 2 or
3 CTO.
Table 2 summarizes the procedural characteristics. Over-
all, multivessel PCI was performed in 67% of cases, and a
complete revascularization was achieved in 84% of patients.
The STAR technique was used in 54 patients: recanali-
zation was achieved in 50 cases, whereas a final TIMI flow
grade of 3 was achieved in only 34 (4.2%); and EES was
used in 16 (47%).
First-generation DES were used in 66% of cases, whereas
EES were used in 34%.
Table 3 summarizes the angiographic and clinical out-
comes. Of 802 patients, 49 were not eligible for angio-
graphic follow-up because of death (n  29: 26 cardiac
eaths and 3 noncardiac deaths) or moderate (n  10) or
evere (n  10) renal insufficiency. Thus, 753 patients were
ligible for the angiographic follow-up , and 616 had
oronary angiography (follow-up rate: 82%). All eligible
atients who did not undergo angiographic follow-up were
live and asymptomatic for angina.
The target CTO vessel reocclusion was revealed in 46
atients (reocclusion rate: 7.5%). The reocclusion rateas 10.1% in patients treated with first-generation DES,
nd 3% in patients treated with EES (p  0.001). The
reocclusion rate was 57% in patients treated using the
STAR technique and 5.1% using non-STAR techniques
(p  0.001). Of 25 patients treated successfully using the
retrograde approach, angiographic follow-up was available for
19, and no reocclusion was revealed. Nonocclusive restenosis
was revealed in 79 patients (nonocclusive restenosis rate
13%).
There was no significant interaction between EES and
year of the index procedure.
By multivariable analysis, the only variables related to
reocclusion were the STAR technique (OR: 29.5, 95% CI:
11.9 to 73.2; p  0.001) and EES (OR: 0.22, 95% CI: 0.09
to 0.54; p  0.001). The only variable related to the risk of
nonocclusive restenosis was the right coronary artery CTO
(OR: 1.64, 95% CI: 1.02 to 2.62, p  0.040).
At 1-year follow-up, the cardiac mortality rate was 3.2%,
the myocardial infarction rate was 0.9%, whereas 103
patients (12.8%) underwent repeat PCI for restenosis or
reocclusion of the CTO target vessel. Major adverse cardiac
events rate was significantly lower in EES than in first-
generation DES (11.6% vs 19%; p  0.005). The target
CTO revascularization rate was 14.1% in patients treated
with first-generation DES, and 10.5% in patients treated
with EES (p  0.139). No patient underwent coronary
Baseline Clinical and Angiographic CharacteristicsTable 1 Baseline Clinical and Angiographic Characteristics
Successful CTO PCI
(n  802)
Age, yrs 68 11
75 233 (29)
Male 680 (85)
Hypertension 485 (60)
Hypercholesterolemia 458 (57)
Current smokers 158 (20)
Diabetes mellitus 200 (25)
Previous myocardial infarction 405 (50)
Previous PCI 289 (36)
Previous coronary surgery 91 (11)
Renal insufficiency, creatinine 250 mol/l 18 (2.2)
ACS 255 (32)
LVEF 44 12
40% 298 (37)
Multivessel disease 660 (82)
3-vessel disease 393 (49)
CTO vessel
LAD 248 (31)
LCX 177 (22)
RCA 329 (41)
Others 48 (6)
Values are mean  SD or n (%).
ACS  acute coronary syndrome(s) (includes unstable angina and non–ST-segment elevation
yocardial infarction); CTO chronic total occlusion; LAD left anterior descending artery; LCX
left circumflex; LVEF left ventricular ejection fraction; PCI percutaneous coronary intervention;
CA  right coronary artery.surgery. Overall, the 3-year event-free survival rate (median:
p
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rate was 55  14% in patients treated with the STAR
technique, and 77  2% in patients treated with a non-
STAR technique (p  0.014) (Fig. 1). At multivariable
analysis by Cox analysis, the variables related to cardiac
mortality were: age 75 years (HR: 4.64, 95% CI: 2.19 to
9.83; p  0.001); left ventricular ejection fraction 0.40
(HR: 7.25, 95% CI: 2.77 to 19; p  0.001); left anterior
descending artery CTO (HR: 2.39, 95% CI: 1.13 to 4.33;
p  0.020); complete revascularization (HR: 0.48, 95% CI:
0.24 to 0.95; p  0.037). Variables related to major adverse
cardiac events were: age75 years (HR: 1.64, 95% CI: 1.17
to 2.31; p  0.004); STAR technique (HR: 2.26, 95% CI:
1.21 to 4.22; p  0.010); left ventricular ejection fraction
0.40 (HR: 1.47, 95% CI: 1.06 to 2.06; p  0.023); left
anterior descending artery CTO (HR: 1.42, 95% CI: 1.02 to
2.01; p  0.046) (Table 4).
Definite stent thrombosis rate was 0.4%.
Table 5 summarizes the matched comparison between
patients treated with first-generation DES and EES (C-
statistic: 0.69 and Hosmer-Lemeshow test p  0.803 for
propensity score analysis). Patients treated with EES had
Procedural CharacteristicsTable 2 Procedural Characteristics
Successful CTO PCI
(n  802)
Occlusion length, mm
Mean 38 21
Median 32 (22–50)
Length 20 597 (74)
Reference CTO vessel diameter, mm
Mean 2.63 0.53
Median 2.60 (2.30–3.0)
Diameter 2.5 mm 190 (24)
Adjunctive rotational atherectomy 37 (4.6)
STAR technique 34 (4.2)
CTO stent implanted, n 1,509
Mean stents/patient 1.88
First-generation DES (PES and SES), % 66
EES, % 34
CTO stent length, mm
Mean 52 30
Median 44 (28–69)
CTO stent length 40 432 (54)
Post-PCI minimum lesion diameter, mm
Mean 2.74 0.49
Median 2.80 (2.50–3.0)
Fluoroscopic time, min
Median 24 (15–36)
Contrast, ml
Median 300 (200–400)
Multivessel PCI 540 (67)
Completeness of revascularization 675 (84)
Values are mean  SD, median interquartile range, or n (%).
DES  drug-eluting stent(s); EES  everolimus-eluting stent; IQR  interquartile range; PES 
aclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); STAR  subintimal tracking and
e-entry; other abbreviations as in Table 1.better clinical and angiographic outcomes.Discussion
The main findings of this study can be summarized as
follows: 1) The use of EES, as compared to first-generation
Clinical and Angiographic OutcomesTable 3 Clinical and Angiographic Outcomes
Successful CTO PCI
(n  802)
1-year clinical outcome
MACE 131 (16)
Cardiac death 26 (3.2)
Myocardial infarction 7 (0.9)
CABG 0
CTO vessel repeat PCI 103 (12.8)
First-generation PES and SES 72/508 (14.1)
EES 31/294 (10.5)
STAR 11/34 (32.3)
Definite stent thrombosis 4 (0.4)
Angiographic outcome (n  616)
Follow-up rate 616/753 (82)
In-segment restenosis or
reocclusion
125 (20)
Reocclusion rate 46 (7.5)
First-generation PES and SES 39/385 (10.1)*
EES 7/231 (3.0)
STAR 16/28 (57)
Values are n (%). *p  0.001 first-generation DES versus second-generation EES.
CABG coronary artery bypass graft; EES everolimus-eluting stent(s); MACEmajor adverse
ardiac event(s); other abbreviations as in Tables 1 and 2.
Figure 1 Kaplan-Meier Analysis of Freedom From MACE
Kaplan-Meier estimates of 3-year event-free survival in patients treated with the
subintimal tracking and re-entry (STAR) technique (red line) and patients
treated with a non-STAR technique (green line). MACE  major adverse cardio-
vascular events.
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a 5-fold decrease in CTO vessel reocclusion rate. 2) The
reocclusion rate with EES was only 3%, and this finding
drives the difference in event-free survival between patients
treated with first-generation DES and EES. 3) The STAR
technique allowed CTO vessel recanalization in nearly all
cases but a final TIMI flow grade of 3 was achieved in
approximately 60% of patients. 4) Patients with a successful
STAR procedure (final TIMI flow grade of 3) had a very
high rate of reocclusion.
The better performance of EES versus first-generation
DES was shown in the SPIRIT (Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System in
the Treatment of Patients With De Novo Native Coronary
Artery Lesions) randomized studies (14–16) that excluded
CTO patients, and also in the COMPARE (Second-
Generation Everolimus-Eluting and Paclitaxel-Eluting
Stents in Real-Life Practice) trial (17), an all-comer ran-
domized study comparing EES with first-generation
paclitaxel-eluting stents. However, this study did not pro-
vide data on the performance of EES in CTO that
accounted for only 3.6% of treated lesions. The increased
efficacy of EES in very long CTO lesions (requiring 40
mm stent length) as compared to first-generation paclitaxel-
eluting stents was shown in a previous nonrandomized study
(12). The current study confirms the increased efficacy of
EES also in shorter CTO lesions.
There are very few data on angiographic follow-up after
PCI using the STAR technique. In the original series of
STAR technique applied to native coronaries described by
Colombo et al. (18), 21 patients had angiographic follow-
up, and the reocclusion rate was 24%. In a second series of
68 patients treated with the STAR technique, the reocclu-
sion rate was 35% (19). However, in this study, the
Predictors of Clinical and Angiographic OutcomeTable 4 Predictors of Clinical and Angiographic Outcome
Clinical Outcome HR 95% CI p Value
Cardiac death
Age 75 yrs 4.64 2.19–9.83 0.001
LVEF 40% 7.25 2.77–19 0.001
LAD-CTO 2.39 1.13–4.33 0.020
Completeness of revascularization 0.48 0.24–0.95 0.037
MACE
Age 75 yrs 1.64 1.17–2.31 0.004
STAR technique 2.26 1.21–4.22 0.010
LVEF 40% 1.47 1.06–2.06 0.023
LAD-CTO 1.42 1.02–2.01 0.046
Angiographic Outcome OR
Reocclusion
STAR technique 29.50 11.9–73.2 0.001
EES 0.22 0.09–0.54 0.001
Nonocclusive restenosis
RCA-CTO 1.64 1.02–2.62 0.040
CI  confidence interval(s); HR  hazard ratio(s); OR  odds ratio(s); other abbreviations as in
Tables 1 to 3.angiographic follow-up rate was only 56%. In a more recentseries that included 74 patients, the reocclusion rate was
41% (follow-up rate: 85%) (20).
The current study shows a very high reocclusion rate
(57%) after a successful CTO PCI using the STAR tech-
nique. This finding suggests limiting the use of this tech-
nique to a very few patients: patients with failed anterograde
or retrograde attempt; patients with severe and refractory
symptoms; and patients with a very high surgical risk despite
a coronary anatomy suitable for bypass grafting.
Study limitations. This is a nonrandomized single-center
study. Despite the shortcomings inherent in all registries,
the study includes the largest series of CTO PCI patients
with angiographic follow-up and provides original insights
into the clinical and angiographic outcomes after successful
DES-supported PCI for CTO. The number of patients
treated with the STAR technique is small, preventing a
definite conclusion on long-term efficacy of this technique.
However, the reported high reocclusion rate is consistent
with the rates reported in previously published small patient
series (8,18,19).
Conclusions
The uses of EES and conventional anterograde or retro-
grade approaches to CTO are associated with very low rates
of target vessel reocclusion. Conversely, the use of the
STAR technique, even successfully, is associated with a very
high rate of target vessel reocclusion.
Baseline Characteristics andOutcome of the P opensity Matched GroupsTable 5 B seline Ch racteristics andOutcome of the Propensity Matched Groups
First-Generation DES
(n  294)
EES
(n  294) p Value
Age 75 yrs 77 (26) 81 (28) 0.710
Male 259 (88) 261 (89) 0.796
Hypertension 168 (57) 185 (63) 0.152
Diabetes mellitus 64 (22) 73 (25) 0.380
Previous myocardial infarction 140 (48) 168 (57) 0.021
LVEF 40% 108 (37) 104 (35) 0.731
Three-vessel disease 136 (46) 130 (44) 0.619
LAD-CTO 107 (36) 96 (33) 0.340
Occlusion length 20 mm 251 (85) 244 (83) 0.429
Reference diameter 2.5 mm 63 (21) 63 (21) 1.00
CTO stent length 40 mm 187 (64) 193 (66) 0.605
Rotational atherectomy 9 (3.1) 12 (4.1) 0.505
STAR technique 12 (4.1) 16 (5.4) 0.439
Complete revascularization 249 (85) 260 (88) 0.183
1-year clinical outcome
MACE 66 (22.4) 34 (11.6) 0.001
Cardiac death 14 (4.8) 3 (1.0) 0.007
Myocardial infarction 8 (2.0) 1 (0.03) 0.019
CTO vessel repeat PCI 50 (17) 31 (10.5) 0.023
Definite stent thrombosis 3 (1.0) 0 0.082
Angiographic outcome 230 231
In-segment restenosis or reocclusion 63 (27) 30 (13) 0.001
Reocclusion 23 (10) 7 (3) 0.002Values are n (%) or n.
Abbreviations as in Tables 1 to 3.
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